在地平线上:一个全球多学科的观点,提供新兴疗法为BCG-先天性高风险NMIBC患者提供
Bernadett E Szabados1,2, Félix Guerrero-Ramos3, Enrique Grande4
1Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK. bernadett.szabados@nhs.net.
将静脉内疗法与免疫检查点抑制剂 (ICI) 结合在一起的新疗法在高风险的非肌肉侵入性膀癌 (NMIBC) 中表现有前途. 多学科护理对于整合这些进展和改善患者的治疗结果至关重要.
科学领域:
- 在瘤学瘤学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 免疫治疗是一种免疫疗法.
背景情况:
- 高风险的非肌肉侵入性膀癌 (NMIBC) 治疗依赖于通过尿道切除和卡尔梅特-盖林菌根 (BCG).
- 复发和进展是常见的,通常需要彻底的囊切除术.
- 由于BCG的短缺和治疗的局限性,人们对新型疗法的需求尚未得到满足.
研究的目的:
- 讨论将新兴疗法,特别是免疫检查点抑制剂 (ICI) 纳入BCG先前高风险NMIBC治疗的最佳实践.
- 突出多学科护理在管理这些新治疗选择中的重要性.
- 解决从泌尿科医生主导的护理转向涉及医疗瘤学的协作模式的范式转变.
主要方法:
- 审查当前的临床经验和新出现的关于高风险NMIBC中的ICI的数据.
- 讨论潜在的多学科护理模式和工作流程.
- 确定成功整合的关键要素,包括沟通,资源和教育.
主要成果:
- 新兴方案将静脉内疗法与全身PD-1/PD-L1 ICI结合起来,目前正在进行第3期试验.
- 集成ICI需要医疗瘤学专业知识来评估患者和毒性管理.
- 包括专业护士在内的多学科护理对于最佳的患者管理至关重要.
结论:
- 在高风险NMIBC中成功实施ICI,多学科护理至关重要.
- 有效的沟通,充足的资源和全面的教育对医疗保健专业人员,患者和护理人员至关重要.
- 这些策略将使符合条件的患者能够从新的治疗方案中受益,改善疾病控制和生活质量.
更多相关视频
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
